Ignite Creation Date:
2025-12-24 @ 3:23 PM
Ignite Modification Date:
2026-05-03 @ 2:06 PM
Study NCT ID:
NCT01458392
Status:
COMPLETED
Last Update Posted:
2022-10-05
First Post:
2011-10-20
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Sponsor:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
A041-03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None